Back to top
more

NuVasive, Inc. (NUVA)

(Delayed Data from NSDQ)

$62.96 USD

62.96
567,418

+0.74 (1.19%)

Updated May 3, 2019 04:00 PM ET

After-Market: $62.96 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Polaris, 58.com, BlackRock, Intuitive Surgical, Medtronic and NuVasive as Zacks Bull and Bear of the Day

by Zacks Equity Research

Polaris, 58.com, BlackRock, Intuitive Surgical, Medtronic and NuVasive as Zacks Bull and Bear of the Day

    Sweta Jaiswal headshot

    3 Stocks to Tap the Minimally-Invasive Surgery Market Boom

    by Sweta Jaiswal

    Consider these three stocks in the rapidly-growing minimally-invasive surgical device market.

      NuVasive's (NUVA) Global Prospects Solid, Competition Rife

      by Zacks Equity Research

      NuVasive (NUVA) demonstrates strong sales growth across all geographies. Competitive landscape is a concern.

        Why is NuVasive (NUVA) Down 5.7% Since its Last Earnings Report?

        by Zacks Equity Research

        NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

          NuVasive (NUVA) Q1 Earnings Miss Estimates, Revenues In Line

          by Zacks Equity Research

          NuVasive (NUVA) gains on continued growth in international business along with strong case volume growth in the U.S. Hardware business in Q1.

            Why Is NuVasive (NUVA) Up 4.6% Since Its Last Earnings Report?

            by Zacks Equity Research

            NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

              NuVasive Gains From International Business Amid Pricing Woes

              by Zacks Equity Research

              Sturdy performance of NuVasive's (NUVA) international business with more than 20% growth for the fifth consecutive quarter raises optimism among investors

                NuVasive (NUVA) Meets Q4 Earnings Estimates, Issues '18 View

                by Zacks Equity Research

                NuVasive (NUVA) gains on continued growth in international business in Q4.

                  Can Segmental Strength Drive Integra's (IART) Q4 Earnings?

                  by Zacks Equity Research

                  Integra LifeSciences (IART) well poised to gain from strength in Orthopedics and Tissue Technologies in Q4.

                    What's in the Cards for Genomic Health (GHDX) in Q4 Earnings?

                    by Zacks Equity Research

                    Similar to last quarter, Genomic Health (GHDX) is expected to gain from higher total product revenues in Q4.

                      International Business Aids NuVasive, Pricing Woe Remains

                      by Zacks Equity Research

                      NuVasive (NUVA) plans to merge its U.S. Commercial and International sales functions into a global commercial organization. Also, several recent FDA approvals are encouraging.

                        NuVasive's SpineTRACK Registry Gains New CMS Designation

                        by Zacks Equity Research

                        NuVasive's (NUVA) receipt of the QCDR designation for its SpineTRACK buoys optimism for the stock. This achievement might add value to cushion its efforts to provide systems-based spine solutions.

                          NuVasive Q4 Preliminary Results Fail to Cheer Investors

                          by Zacks Equity Research

                          NuVasive (NUVA) continues to witness sequential growth in international revenues and expects substantial tax savings from the recent U.S. tax reform.

                            NuVasive (NUVA) Global Prospects Solid, Pricing Woes Remain

                            by Zacks Equity Research

                            NuVasive (NUVA) witnesses solid top-line contributions from the international business.

                              NuVasive (NUVA) to Acquire SafePassage, Strengthens IONM

                              by Zacks Equity Research

                              NuVasive's (NUVA) combined entity with SafePassage seems strategic as the move will fortify the NuVasive Clinical Services' (NCS) status as the largest U.S. provider of outsourced IONM services.

                                NuVasive (NUVA) in Focus: Stock Moves 8.4% Higher

                                by Zacks Equity Research

                                NuVasive, Inc. (NUVA) saw its shares rise over 8% on the day after the company reported better-than-expected third-quarter results and announced a major stock repurchase program.

                                  New Strong Sell Stocks for October 26th

                                  by Zacks Equity Research

                                  Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

                                    NuVasive (NUVA) Q3 Earnings Top, Revenues Lag, Guidance Cut

                                    by Zacks Equity Research

                                    NuVasive's robust top-line growth in Q3 was driven by strong international performance. However, U.S. sales declined on procedural volume challenges and an adverse impact of the recent natural disasters.

                                      NuVasive's TLX Interbody System Gets Expanded FDA Approval

                                      by Zacks Equity Research

                                      NuVasive (NUVA) leaves no stone unturned to cash in on the rapidly-evolving spine market.

                                        NuVasive's (NUVA) PRECICE System Gets Expanded FDA Approval

                                        by Zacks Equity Research

                                        NuVasive's (NUVA) latest receipt of expanded FDA 510(k) approval for PRECICE is likely to fortify its hold in the limb reconstruction and trauma market.

                                          NuVasive Acquires Vetera Spine, Grows With Spinal Hardware

                                          by Zacks Equity Research

                                          NuVasive aims to market and distribute Vetera Spine's FDA-approved COHERE Cervical and COALESCETM Lumbar Interbody fusion devices in the United States.

                                            NuVasive Launches Breakthrough in MIS Surgery -- LessRay

                                            by Zacks Equity Research

                                            NuVasive's latest LessRay system reduces radiation emission and exposure. The stock is likely to gain on number of vital developments despite a brief dull phase in between.

                                              NuVasive Announces Vertera Spine Buyout, Boosts Implants Suite

                                              by Zacks Equity Research

                                              NuVasive (NUVA) to add three-dimensional porous interbody technology across polyetheretherketone (PEEK) material as well through the Vertera Spine buyout.

                                                NuVasive Grows in Pediatric Deformity With New FDA Approval

                                                by Zacks Equity Research

                                                NuVasive (NUVA) has progressed with its 'Embracing the Journey Together' program with the FDA nod to use the company's redesigned MAGEC system with its RELINE Small Stature system.

                                                  NuVasive (NUVA) to Expand San Diego Global Headquarters

                                                  by Zacks Equity Research

                                                  Apart from introducing sophisticated features at the facility, NuVasive (NUVA) plans to open an innovation center of excellence at the San Diego global headquarters.